论文部分内容阅读
目的观察培哚普利联合卡维地洛治疗慢性充血性心力衰竭的临床疗效及安全性。方法将我院近年来收治的慢性充血性心力衰竭患者86例,随机分为观察组43例和对照组43例,对照组给予常规强心、利尿、扩血管等基础治疗,观察组在常规治疗基础上加用培哚普利2～4mg/次,1次/d,卡维地洛3.125～6.25mg/次,2次/d,口服,疗程10周,观察两组临床疗效及治疗前后心率、血压、心功能改变情况及不良反应。结果观察组总有效率为93.0%(40/43),对照组总有效率为76.7%(33/43),两组疗效比较差异有统计学意义(P<0.05),两组均未出现明显不良反应。结论培哚普利联合卡维地洛治疗慢性充血性心力衰竭临床疗效明显优于常规基础治疗组,用药安全方便,患者依从性好,值得临床推广。
Objective To observe the clinical efficacy and safety of perindopril combined with carvedilol in the treatment of chronic congestive heart failure. Methods 86 cases of chronic congestive heart failure admitted to our hospital in recent years were randomly divided into observation group (43 cases) and control group (43 cases). The control group was given conventional cardioplegia, diuretic, vasodilator and other basic treatment. The observation group received routine treatment On the basis of adding perindopril 2 ~ 4mg / time, 1 / d, carvedilol 3.125 ~ 6.25mg / times, 2 times / d, for 10 weeks, the clinical efficacy and heart rate before and after treatment were observed , Blood pressure, cardiac function changes and adverse reactions. Results The total effective rate was 93.0% (40/43) in the observation group and 76.7% (33/43) in the control group, with significant difference between the two groups (P <0.05). There was no significant difference between the two groups Adverse reactions. Conclusion The clinical efficacy of perindopril combined with carvedilol in the treatment of chronic congestive heart failure is significantly better than that of the conventional basic treatment group. The drug is safe and convenient, and the patients have good compliance and worthy of clinical promotion.